As mTOR activity is commonly dysregulated in the majority of human cancers, our work raises the plausible hypothesis that part of the beneficial effect of FASN inhibition in cancer treatment may be due to the concomitant drop in mTORC1 signalling84. The gene discussed is MTOR; the disease is cancer.